JP Morgan Chase’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-477,597
| Closed | -$13.2M | – | 7783 |
|
|
2026
Q1 | $13.2M | Buy |
477,597
+396,111
| +486% | +$10.1M | ﹤0.01% | 2437 |
|
|
2025
Q4 | $2.04M | Sell |
81,486
-160,409
| -66% | -$4.06M | ﹤0.01% | 4057 |
|
|
2025
Q3 | $5.87M | Sell |
241,895
-186,539
| -44% | -$3.32M | ﹤0.01% | 3206 |
|
|
2025
Q2 | $5.63M | Buy |
428,434
+260,702
| +155% | +$3.3M | ﹤0.01% | 3040 |
|
|
2025
Q1 | $2.41M | Sell |
167,732
-22,653
| -12% | -$371K | ﹤0.01% | 3737 |
|
|
2024
Q4 | $3.19M | Buy |
190,385
+54,482
| +40% | +$903K | ﹤0.01% | 3779 |
|
|
2024
Q3 | $2.17M | Buy |
135,903
+129,335
| +1,969% | +$1.58M | ﹤0.01% | 3943 |
|
|
2024
Q2 | $59.3K | Sell |
6,568
-20,697
| -76% | -$196K | ﹤0.01% | 5783 |
|
|
2024
Q1 | $308K | Buy |
27,265
+16,635
| +156% | +$158K | ﹤0.01% | 5087 |
|
|
2023
Q4 | $84.6K | Buy |
10,630
+529
| +5% | +$3.55K | ﹤0.01% | 5810 |
|
|
2023
Q3 | $65.4K | Sell |
10,101
-49,263
| -83% | -$337K | ﹤0.01% | 5704 |
|
|
2023
Q2 | $367K | Sell |
59,364
-39,861
| -40% | -$189K | ﹤0.01% | 4681 |
|
|
2023
Q1 | $382K | Buy |
99,225
+86,478
| +678% | +$316K | ﹤0.01% | 4660 |
|
|
2022
Q4 | $39K | Buy |
12,747
+9,356
| +276% | +$34.7K | ﹤0.01% | 5698 |
|
|
2022
Q3 | $14K | Sell |
3,391
-175,023
| -98% | -$800K | ﹤0.01% | 5891 |
|
|
2022
Q2 | $869K | Buy |
178,414
+173,698
| +3,683% | +$1.11M | ﹤0.01% | 4199 |
|
|
2022
Q1 | $42K | Buy |
4,716
+207
| +5% | +$1.89K | ﹤0.01% | 5859 |
|
|
2021
Q4 | $51K | Buy |
4,509
+2,681
| +147% | +$36.1K | ﹤0.01% | 5934 |
|
|
2021
Q3 | $30K | Sell |
1,828
-262
| -13% | -$5.42K | ﹤0.01% | 5959 |
|
|
2021
Q2 | $47K | Buy |
+2,090
| New | +$49.1K | ﹤0.01% | 5747 |
|
JP Morgan Chase's CNTA Position: Q2 2026 in Review
JP Morgan Chase sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 477,597 shares — an estimated $13.2M sold.
JP Morgan Chase first reported a position in CNTA in Q2 2021 and held it in 20 quarters. The position peaked at $13.2M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- JP Morgan Chase reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 477,597 Centessa Pharmaceuticals shares in Q2 2026, an estimated $13.2M.
- JP Morgan Chase first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 20 quarters.
- JP Morgan Chase's Centessa Pharmaceuticals position peaked at $13.2M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.